Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

McKesson (MCK) Beats Earnings & Revenue Estimates in Q2

McKesson Corporation MCK reported second-quarter fiscal 2018 (ended Sep 30, 2017) earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.78. Earnings also surpassed the year-ago figure of $2.96.
McKesson posted sales of $52.1 billion, beating the Zacks Consensus Estimate of $51.6 billion. This was up from $50.0 billion last year.

Quarter in Detail

McKesson operates through two segments, Distribution Solutions and Technology Solutions. All growth rates given below are on a year-over-year basis.

Distribution Solutions revenues were $51.9 billion for the quarter, up 5% on a reported and constant currency basis.

However, revenues from the Technology Solutions business declined from $680 million in the year-ago quarter to $120 million. This was due to the bifurcation of the Technology Solutions businesses to the Change Healthcare joint venture on Mar 1. The segment reflects only the numbers from the Enterprise Information Solutions business.

 

McKesson Corporation Price, Consensus and EPS Surprise

 

McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote

Financial Condition

As of Sep 30, McKesson had $2.6 billion in cash and cash equivalents against $2.8 billion as of Mar 31. During the reported quarter (ended Sep 30), the company generated cash worth $1.3 million from operations. During the first half of the year, McKesson repaid $545 million in long-term debt, paid $1.9 billion for acquisitions, repurchased $650 million of its common stock, invested $255 million internally and paid $121 million in dividends.

Fiscal 2018 Outlook

McKesson expects GAAP earnings per diluted share in the range of $4.80 to $6.90 for the fiscal year ending Mar 31, 2018. Adjusted Earnings for the same are expected in the range of $11.80 to $12.50.

Zacks Rank

McKesson currently carries a Zacks Rank #3 (Hold).

Companies Reporting Solid Earnings Results

Intuitive Surgical Inc ISRG posted adjusted earnings of $2.77 per share in the third quarter of 2017, beating the Zacks Consensus Estimate of $1.97 on stellar revenue growth. The stock has a Zacks Rank #2 (Buy).

PetMed Express, Inc’s PETS adjusted earnings per share of 43 cents for the second quarter of fiscal 2018 were up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock has a Zacks Rank #1 (Strong Buy). You can see https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICI... _1link">the complete list of today’s Zacks #1 Rank stocks here.

Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Third-quarter worldwide sales came in at $6.83 billion, up 28.8% year over year. Abbott carries a Zacks Rank #2.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PetMed Express, Inc. (PETS): Free Stock Analysis Report
 
Abbott Laboratories (ABT): Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
 
McKesson Corporation (MCK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research